2019 CMHC Annual - Virtual Exhibit Hall
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Vascepa® (icosapent ethyl), Amarin's first FDA approved product, is a pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa visit www.vascepa.com. For more information visit www.amarincorp.com.
Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd. Daiichi Sankyo, Inc. is a member of the Daiichi Sankyo Group and is focused on the development of oncology therapies and specialty medicines. Daiichi Sankyo, Inc. medicines approved in the U.S. include therapies for hypertension, pain management, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, opioid-induced constipation, IV iron therapy and metastatic melanoma.
CARDIOLOGY TODAY AND ENDOCRINE TODAY are reporting LIVE at CMHC! In print and online, you’ll get the latest meeting coverage along with expert perspective from our renowned Editorial Boards and other leading clinicians. Explore videos, In the Journals and resources that are relevant to your practice. Stop by our booth for a free issue of Cardiology Today and Endocrine Today.